



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C07K 16/28, C07H 21/04, C12N 5/10, C12P 21/08, A61K 39/395</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/47923</b> <b>(43) International Publication Date:</b> 29 October 1998 (29.10.98)
<b>(21) International Application Number:</b> PCT/US98/07810 <b>(22) International Filing Date:</b> 16 April 1998 (16.04.98) <b>(30) Priority Data:</b> 60/044,705 18 April 1997 (18.04.97) US <b>(71) Applicant (for all designated States except US):</b> TANOX BIOSYSTEMS, INC. [US/US]; 10301 Stella Link, Houston, TX 77025 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> NI, Paul [CN/US]; 5415 Braesvalley No. 770, Houston, TX 77096 (US). SUN, Bill, N., C. [US/US]; 4901 Welford Drive, Bellaire, TX 77401 (US). SUN, Cecily, R., Y. [US/US]; 4901 Welford Drive, Bellaire, TX 77401 (US). YU, Liming [CN/US]; 11171 Camino Ruiz No. 62, San Diego, CA 92126 (US). <b>(74) Agent:</b> MIRABEL, Eric; Tanox Biosystems, Inc., 10301 Stella Link, Houston, TX 77025 (US).		<b>(81) Designated States:</b> AL, AU, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SD, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** IL-5R ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND OTHER ALLERGIC DISEASES**(57) Abstract**

Disclosed are antagonist molecules, including monoclonal antibodies, which bind to the extracellular portion of the  $\alpha$  chain of the IL-5 receptor protein, and inhibit proliferation of eosinophils as measured in an *in vitro* assay. Two such monoclonal antibodies which were particularly effective in such binding were found to bind, respectively, to the portion of the sequence of human IL-5 receptor shown in SEQ ID NO:2, and to a conformational epitope.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# IL-5R Antagonists for Treatment of Inflammation, Asthma and Other Allergic Diseases

## FIELD OF THE INVENTION

- 5           The invention relates to antagonists for the interleukin-5 receptor for treating inflammation and asthma and other allergic diseases.

## BACKGROUND OF THE INVENTION

- The pathology of asthma is associated with infiltration of eosinophils into the bronchoalveolar tissue. *In vitro* studies have shown that the
- 10       accumulation of eosinophils is associated with the presence of TH2 cells and mast cells and the production of interleukin-5 ("IL-5") (Huston, D.P., Postgraduate Syllabus, pp. 127-142 (1997)). Animal studies further confirmed that IL-5 plays a key role in the asthmatic response. A neutralizing anti-IL-5 antibody has been shown to inhibit antigen or virus
- 15       induced airway hyper-responsiveness and eosinophil inflammation in the airways of mice (Kung, TT., American J. Respiratory Cell & Molecular Biology, 1995, 13:360-5).

- Eosinophils have a receptor protein for IL-5 on their surface. The interaction between this receptor and IL-5 may be associated the
- 20       inflammatory response, and particularly, with asthma. Preventing this interaction could therefore play an important role in reducing inflammation and/or asthma. There has been one suggestion of use of an antagonist

EP 0811691 A1. The molecules of the present invention are believed to be  
25 superior to those disclosed therein.

### SUMMARY OF THE INVENTION

The invention includes antagonists of the IL-5 receptor ("IL-5R"), for example, antibodies and fragments, homologues and analogues thereof, as well as peptides, nucleotides, or other antagonist molecules, including  
30 immunoglobulin fragments like Fab, (Fab')<sub>2</sub> and Fv, and small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. These receptor antagonists can bind to the IL-5R on the eosinophils or eosinophil progenitor cells but do not stimulate them. Therefore, they compete with IL-5 for receptor sites, and inhibit the  
35 functional activity of IL-5. This in turn inhibits the pathogenesis of inflammation, asthma and the airway allergic response. These antagonists can all be screened using methods that are the same or essentially the same (with some modification) as those described below, which were used to isolate certain antibodies which are IL-5R antagonists.

40 The preferred anti-IL-5R monoclonal antibodies of the invention are chimeric, humanized, or human antibodies, or other antibody derivatives which are less immunogenic than antibodies which are wholly non-human, such as murine antibodies. One preferred monoclonal antibody of the invention binds to an epitope on human IL-5R having the sequence set  
45 forth in SEQ ID NO: 1. Another binds to a conformational epitope on the

human IL-5R. Other preferred antagonist molecules would be expected to bind to the same epitopes. However, the screening methods described below can also be used to isolate antibodies or other antagonist molecules binding to other epitopes, some of which may be superior in their antagonist effect to those targeted by the antibodies 165-4 and 165-13 described below.

The antibodies and other antagonist molecules of the invention can be used therapeutically or diagnostically. In diagnostic applications, they can be used to detect or quantify eosinophils in a body fluid sample, using conventional analytical techniques.

#### BRIEF DESCRIPTION OF THE FIGURES:

Figure 1 depicts the specific binding of three different antagonist monoclonal antibodies to human IL-5 receptor alpha chain as determined by ELISA. An isotype matched monoclonal antibody was set as a control in this assay.

Figure 2 depicts blocking of human IL-5 binding to IL-5 receptor alpha chain by three different anti-IL-5R $\alpha$  antagonist monoclonal antibodies, as determined by ELISA. The decrease in OD<sub>450/570</sub> readings indicates the decrease of IL-5R $\alpha$ /IgG4Fc binding to human IL-5, resulting from competition of the antagonist monoclonal antibodies binding to human IL-5 receptor alpha chain.

Figure 1 depicts competition of three different antagonist

monoclonal antibodies binding to free IL-5R $\alpha$ /IgG4Fc with the antagonist  
70 monoclonal antibody 165-13, as determined by ELISA.

Figure 4 depicts proliferation inhibition of the IL-5 dependent human cell line TF-1 by two different human IL-5R $\alpha$  antagonist antibodies in the presence of rhIL-5 (A), or rmIL-5 (B) with a final concentration of 0.3 ng/ml, by MTT assay. The irrelevant isotype matched control monoclonal  
75 antibody 165-21 had no effect.

Figure 5 depicts comparison of proliferation inhibition effects of soluble human IL-5 receptor alpha chain and human IL-5R $\alpha$  antagonist monoclonal antibody 165-13 in the presence of soluble hIL-5 with a final concentration of 0.3 ng/ml by MTT assay.

80 Figure 6 depicts the results of the eosinophil adherence assays. hIL-5 stimulated eosinophils adhere to human IgG coated wells in a dose dependent manner. When different concentrations of the anti-IL-5 monoclonal antibody 165-13 was added to the eosinophil cultures, the stimulatory effect of hIL-5 was inhibited in a dose-dependent manner,  
85 whereas the irrelevant isotype matched control monoclonal antibody had no effect.  $\square$  represents IL-5 alone;  $\blacktriangle$  represents IL-5 and the 165-13 mAb at 10 $\mu$ g/ml;  $\blacklozenge$  represents IL-5 and the 165-13 mAb at 2 $\mu$ g/ml;  $\bullet$  represents IL-5 and the 165-13 mAb at 0.4 $\mu$ g/ml;  $\circ$  is an isotype control antibody; and  $\nabla$  depicts no IL-5 added.

90

MAKING AND USING THE INVENTION

The IL-5R consists of an IL-5-binding  $\alpha$  chain and a non-binding  $\beta$  chain, which is shared with the IL-3 receptor and the GM-CSF receptor. Therefore, preferred antagonists should target the  $\alpha$  chain rather than the  $\beta$  chain. Such molecules can be of a number of different types, including antibodies, fragments, homologues and analogues thereof, as well as peptides, oligonucleotides, peptidomimetics, organic compounds and other small molecules targeting the  $\alpha$  chain and acting as antagonists. All these antagonists can be screened by methods similar to those used to screen for the preferred antibodies, as described below.

100

In one embodiment, the invention relates to anti-IL-5R  $\alpha$  chain antagonist monoclonal antibodies. Monoclonal antibodies can be produced by immunization and fusion, or production from isolated lymphocytes and EBV transformation. If one is producing them through immunization, the anti-IL-5R  $\alpha$  chain peptide, or a fragment or derivative thereof, is preferred for the immunogen, and more preferably, the portion of this peptide which lacks a substantial hydrophobic region.

105

The anti-IL-5R  $\alpha$  chain peptide is a single chain peptide. One of the methods to make such peptides more immunogenic and more suitable for antibody generation is to produce an Fc fusion protein, which includes this peptide fused with a Fc portion of an immunoglobulin, optionally with a

110

immunogenicity of the chimeric protein, but also simplifies purification of the immunogen when using affinity chromatography. The specific method of making and purifying this fusion protein is described in Examples 2 to 5.

115 It should be understood that other immunogens can also be used, including portions or fragments of the IL-5R  $\alpha$  chain, and, preferably, any extracellular portion which is exposed and accessible for antibody binding.

The immunogens so generated can be used to make polyclonal or monoclonal antibodies, or fragments thereof, or can be used to screen  
120 libraries (including phage display libraries and peptide or compound libraries) for molecules which bind thereto. Such methods of producing antibodies and fragments, and of screening, are well known in the art. The molecules selected by these screening methods can then be further characterized for antagonist activity, as described below.

125 More specifically, the antagonist antibodies of the invention can be generated by immunizing rodents (e.g. mice, rats, hamsters or guinea pigs) with the IL-5R immunogen or the fusion protein described above. Other animals can also be immunized, e.g. non-human primates, which would produce less immunogenic antibodies. Hybridomas can be  
130 generated by conventional procedures by fusing B lymphocytes from the immunized animals with myeloma cells (e.g. Sp2/0 and NS0), as described by G. Köhler and C. Milstein (*Nature*, 1975: 256: 495-497). In addition, antibody fragments can be generated by screening of



recombinant single-chain Fv or Fab libraries from human B lymphocytes in  
135 phage-display systems. Although the methods described in Examples 6  
to 11 below were used to make the antibodies of the invention, any of the  
foregoing methods could be used to make such antibodies. These  
antibodies, or fragments, homologues or analogues thereof, can then be  
characterized for their antagonist effect, as described in the examples.

140 The epitope to which the antagonist molecules bind can be  
determined by the method described in Example 12, or by other methods  
of epitope mapping, which are well known in the art. The epitope to which  
the molecules bind may be linear or conformational. The molecules which  
145 bind to such epitopes, including antibodies, fragments, homologues and  
analogues thereof, are described below and included within the invention.

The *in vivo* biofunctional activity of antagonist molecules can be  
determined by animal studies. The molecules could be applied to the  
animal's lung surface before contacting the lungs with an allergen. The  
eosinophil infiltration into the lungs could then be measured and  
150 compared with a control to determine the effectiveness of the molecule in  
asthma or allergic disease treatment.

For administration to humans, the antibodies of the invention would  
preferably be administered as chimeric, humanized or human antibodies.  
Such antibodies can reduce immunogenicity and thus avoid or minimize a

preferable that the antibody administered be IgG<sub>4</sub>, IgG<sub>2</sub>, or other genetically mutated IgG or IgM which does not augment antibody-dependent cellular cytotoxicity (S.M. Canfield and S.L. Morrison, *J. Exp. Med.*, 1991: 173: 1483-1491) and complement mediated cytotoxicity (Y.Xu et al., *J. Biol. Chem.*, 1994; 269: 3468-3474; V.L. Pulito et al., *J. Immunol.*, 1996; 156: 2840-2850).

Chimeric antibodies are produced by recombinant processes well known in the art, and have an animal variable region and a human constant region. Humanized antibodies have a greater degree of human characteristics than do chimeric antibodies. In a humanized antibody, only the complementarity determining regions (CDRs), which are responsible for antigen binding and specificity, are animal derived and have an amino acid sequence corresponding to the animal antibody. Substantially all of the remaining portions of the molecule (except, in some cases, small portions of the framework regions within the variable region) are human derived and correspond in amino acid sequence to a human antibody. See L. Riechmann et al., *Nature*, 1988; 332: 323-327; G. Winter, *United States Patent No. 5,225,539*; C. Queen et al., *United States Patent No. 5,585,089*.

Human antibodies can be made by several different ways, including immunization and fusion of cells obtained from transgenic mice expressing human immunoglobulins, or from severe combined

immunodeficient (SCID) mice transplanted with human B lymphocytes, which are then used to produce hybridomas producing the human  
180 antibodies. Transgenic mice are available from Abgenix, Inc., Fremont, California, and Medarex, Inc., Annandale, New Jersey. Alternatively, one can use human immunoglobulin expression libraries (Stratagene Corp., La Jolla, California) to produce fragments of human antibodies ( $V_H$ ,  $V_L$ , Fv, Fd, Fab, or (Fab')<sub>2</sub>, and use these fragments to construct whole human  
185 antibodies using techniques similar to those for producing chimeric antibodies. Single peptide chain binding molecules in which the heavy and light chain Fv regions are connected can be made by known methods. (A. Plüchhün. *Methods: a companion to Meth. Enzymol.*, 1991: 2: 88-96; M. Whitlow and D. Filpula, *ibid*, 97-105), as can Fab fragments  
190 (M.J. Evans et al., *J. Immunol. Meth.*, 1995; 184: 123-138), and other fragments. All of the wholly and partially human antibodies and fragments are less immunogenic than wholly animal or murine monoclonal antibodies. All such molecules are therefore less likely to evoke an immune or allergic response and therefore are better suited for *in vivo*  
195 administration in humans than animal or murine antibodies, especially when repeated or long-term administration is necessary.

Based on the molecular structures of the variable regions of the antibodies of the invention, one could use molecular modeling and rational

200 molecular structures of the binding region of the antibodies and are also effective IL-5R antagonists. These small molecules can be peptides, peptidomimetics, oligonucleotides, or other organic compounds. Alternatively, one can screen libraries of such molecules by the methods set forth in the examples below. All such methods are known to those  
205 skilled in the art, and would yield small molecules which are effective antagonists.

**Example 1. Eosinophil isolation:**

Fifty milliliters of buffy coat unit (prepared from 450 ml blood, Houston Blood Center, Houston, TX) were diluted with equal volume of  
210 buffer A (13.8 mM Na<sub>3</sub> citrate-2H<sub>2</sub>O, 1% BSA in PBS, pH 7.0). Forty microliters of diluted blood were overlaid onto 50 ml conical tubes containing 10 ml of Ficoll-Paque, and then centrifuged at 18°C - 20°C at 400 g (IEC, 1300rpm) for 30 minutes. After collection of granulocytes (including contaminating erythrocytes) from the bottom of the tubes, the  
215 erythrocytes were lysed with 5 x volume of an ice-cold isotonic ammonium-chloride solution (0.83% NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub> and 0.1 mM EDTA) at 0°C for 15 minutes. After centrifugation for 7 minutes at 400g and 4°C, the granulocytes were washed with 1 x PBS plus 1% BSA, suspended in the same solution and then incubated for 30 minutes at  
220 37°C. The cells were washed with 1 x buffer A, and resuspended at a concentration of  $7.5 \times 10^7$  cells/ml in buffer A. After incubation of the cells for 5 minutes at 37°C, 1  $\mu$ l of FMLP (10  $\mu$ M in PBS) was added and

incubated for 10 minutes. One ml of cell suspension was laid onto a 2-layer Percoll gradient in which 1 ml of Percoll (density: 1.100 g/ml) was  
225 inserted in the bottom and another 4 ml of Percoll (density: 1.082 g/ml) on the top in a 15 ml conical tube. The eosinophils from the interface between the two Percoll layers were collected, after centrifugation at 1000g for 15 minutes at room temperature.

**Example 2. Cloning of the cDNA segment encoding human IL-5  
230 receptor alpha chain.**

Total RNA was prepared by the Ultraspec-3 RNA isolation kit from about  $10 \times 10^6$  eosinophil cells obtained as above, according to the instructions of the manufacturer (Biotech Laboratories Inc., Houston, TX). The single strand cDNA for human IL-5 receptor alpha chain was  
235 synthesized by a reverse transcription reaction in which about 5  $\mu$ g of total RNA obtained as above were added into 20  $\mu$ l of reaction mixture, according the protocol of the manufacturer (Gibco BRL, Gaithersburg, MD). 2  $\mu$ l of this reverse transcription reaction mixture was added into 100  $\mu$ l of PCR reaction mixture which contains two primers (97320-1: TAA  
240 AGC TTG ACA GGA TAT GAT CAT CGT (SEQ ID NO:3); 97320-3: TCG GAT CCC ACA TAA ATA GGT T (SEQ ID NO:4)) at a final concentration of 200 nM. PCR reaction was carried out in the Geneamp 9600 (Perkin Elmer). After precipitation, the PCR product was digested with BamH1 and HindIII, and ligated into the cloning vector pUC18, which was also  
digested with BamH1 and HindIII, yielding the recombinant plasmid pN18.

Both strands of the insert in the plasmid pN10 were confirmed by DNA sequencing.

**Example 3. Construction of the mammalian expression plasmid for human IL-5R $\alpha$ /IgG4Fc chimeric protein:**

250

The DNA fragment encoding the extracellular portion of human IL-5R $\alpha$  chain was isolated from the plasmid pN10 by digestion with HindIII and BamHI, and inserted into the plasmid pcDNA3Fc, which contains an inserted DNA fragment encoding human IgG4Fc and a short DNA  
255 fragment encoding a peptide linker, yielding the mammalian expression plasmid pN3. In this expression plasmid pN3 the expression of the chimeric protein, consisting of the extracellular portion of the human IL-5R $\alpha$  chain in-frame fused with the linker and IgG4Fc, is under the control of hCMV promoter. After linearization with BspC1, the plasmid pN3 was  
260 electrotransfected into NSO cells, using a BioRad apparatus.

**Example 4. Expression of human IL-5R $\alpha$ /IgG4Fc in mammalian cells:**

NSO cells were transfected with linearized pN3.  $4 \times 10^7$  log-phase NSO cells was harvested and resuspended in 0.8 ml IMDM medium supplemented with 2% FBS. After incubation with 10  $\mu$ g of linearized  
265 plasmid DNA for 10 minutes on ice, the cell mixture was subjected to electroporation at 200 volts and 960  $\mu$ F, using a BioRad apparatus. After keeping it on ice for 20 minutes, 100  $\mu$ l of cell suspension was added to each well of about twenty 96-well plates. Two days later, another 100  $\mu$ l of the same IMDM medium but containing G418 (Gibco BRL, Gaithersburg,

270 MD) was added into each wells to make the final concentration of G418  
0.8 mg/ml. After 10 days, culture supernatants were withdrawn.

Screening for the expression of the extracellular portion of human  
IL-5 receptor alpha chain/IgG4Fc fusion protein was done by ELISA as  
follows. The wells of Immulon 2 plates (Dynatech Laboratories, Chantilly,  
275 VA) were precoated by adding 50  $\mu$ l of goat anti-human IgG(Fc) antibody  
at concentration of 1  $\mu$ g/ml and stored overnight at room temperature.  
After the coating solution was removed by flicking the plates, 200  $\mu$ l of  
BLOTTO (5% non-fat dry milk in PBST) was added to each well at room  
temperature to block non-specific bindings. One hour later, wells were  
280 washed with PBST buffer (PBS containing 0.05% Tween 20). Fifty  
microliters of culture supernatants from each well in the transfection plates  
were collected and mixed with 50  $\mu$ l of BLOTTO, and then added to  
individual wells of the microplates. After one hour of incubation at room  
temperature, the wells were washed with PBST. The bound extracellular  
285 human IL-5 receptor alpha chain/IgG4Fc fusion protein was detected by  
reaction with horseradish peroxidase-conjugated goat anti-human IgG(Fc)  
(Jackson ImmunoResearch Laboratories, West Grove, PA), which was  
diluted at 1:2000 in BLOTTO. Peroxidase substrate solution containing  
0.1% 3,3',5,5' tetramethyl benzidine (Sigma, St. Louis, MO) and 0.0003%  
290 hydrogen peroxide (Sigma) was added to each well for color

50  $\mu$ l of 0.2 M  $\text{H}_2\text{SO}_4$  per well. The  $\text{OD}_{450-570}$  reading of the reaction mixture was measured with a BioTek ELISA Reader (BioTek Instruments, Winooski, VT).

295        The transfectants with high  $\text{OD}_{450-570}$  reading were picked up and single cell cloning was performed by the limiting dilution method. The ELISA as above was repeated to more specifically identify the high producer cell lines expressing the fusion protein of the extracellular portion of the human IL-5 receptor alpha chain/IgG4Fc chimeric protein.

300        **Example 5. Purification of the extracellular portion of human IL-5 receptor alpha chain/IgG4Fc chimeric protein:**

Two liters of the culture supernatant from the transfectant cells expressing the extracellular portion of human IL-5 receptor alpha chain/IgG4Fc chimeric protein was collected, and this chimeric protein  
305        was purified by Prosep-A affinity chromatography, according to the manufacturer's instruction (Bioprocessing Inc., Princeton, NJ). The purity of this purified chimeric protein was determined by both SDS-PAGE and immunoblotting.

310        **Example 6. Hybridoma generation:**

Five BALB/c mice, 8 weeks old, were injected subcutaneously with 30  $\mu$ g of purified the extracellular portion of human IL-5 receptor alpha chain/IgG4Fc chimeric protein emulsified with complete Freund's adjuvant (Difco Laboratories, Detroit, MI) in 200  $\mu$ l of phosphate buffered saline  
315        (PBS), pH 7.4. The mice were boosted after 2 and 4 weeks with the same



antigen in incomplete Freund's adjuvant. Two weeks later and three days prior to sacrifice, the mice were given a final booster injection i.p. and their spleen cells were fused with Sp2/0 myeloma cells.  $5 \times 10^8$  of the Sp2/0 cells and an equal number of spleen cells were fused in a medium containing 50% polyethylene glycol (MW 1450)(Kodak, Rochester, NY) and 5% dimethylsulfoxide (Sigma Chemical Co., St. Louis, MO). The cells were adjusted to a concentration of  $5 \times 10^4$  spleen cells per 200  $\mu$ l of the suspension in Iscove medium (Gibco BRL, Gaithersburg, MD), supplemented with 10% FBS, 100 units/ml of penicillin, 100  $\mu$ g/ml of Streptomycin, 0.1 mM hypoxanthine, 0.4  $\mu$ M aminopterin and 16  $\mu$ M thymidine. Two hundred microliters of the cell suspension was added to each well of one hundred 96-well microculture plates. After about ten days culture supernatants were withdrawn to screen for the antibodies' ability to compete for binding to the human IL-5 receptor alpha chain/IgG4Fc chimeric protein with human IL-5 protein. The competitive hybridoma colonies from these supernatants were further subcloned and expanded.

### Example 7. Competitive ELISA:

For screening antagonist antibodies against human IL-5R $\alpha$  from the hybridoma supernatants, one hundred Immulon 2 microtiter plates were precoated with rat anti-human IL-5 monoclonal antibody JES1 (R&D Biosystems) at the final concentration of 1  $\mu$ g/ml in PBS. The plates were incubated at 4°C overnight. Fifty  $\mu$ l of BL OTCG containing 100  $\mu$ l of anti-human IL-5

concentration of 0.06  $\mu\text{g/ml}$  was placed in each well and kept at room  
340 temperature for one hour. After washing with PBST, 100  $\mu\text{l}$  of mixture  
containing 50  $\mu\text{l}$  of the hybridoma supernatants and 50  $\mu\text{l}$  of human IL-  
5 $\alpha$ /IgG4Fc chimeric protein at a final concentration of 0.5  $\mu\text{g/ml}$  was  
added to each well in these plates, and maintained for one hour at room  
temperature. After washing with PBST, 50  $\mu\text{l}$  of goat anti-human IgG(Fc)  
345 conjugated with horseradish peroxidase (diluted 1:5000) was added to  
each well, and incubated for one hour at room temperature. After  
washing with PBST, peroxidase substrate solution containing 0.1%  
3,3,5,5 tetramethyl benzidine (Sigma, St. Louis, MO) and 0.0003%  
hydrogen peroxide (Sigma) was added to each well for color  
350 development. The reaction was terminated after 30 minutes by adding of  
50  $\mu\text{l}$  of 0.2 M  $\text{H}_2\text{SO}_4$  per well. The  $\text{OD}_{450-570}$  reading of the reaction mixture  
was measured with a BioTek ELISA Reader (BioTek Instruments,  
Winooski, Vermont). Lower  $\text{OD}_{450-570}$  readings of the wells indicated  
stronger inhibition ability of the supernatant to interaction of IL-5 with the  
355 IL-5 receptor alpha chain.

To test binding abilities of these purified antagonist  
monoclonal antibodies obtained as in Example 8 below, the following  
procedure was performed. 50  $\mu\text{l}$  of goat anti-mouse antibody IgG(Fc) in  
BLOTTO at a final concentration of 0.5  $\mu\text{g/ml}$  per well was precoated at  
360 room temperature overnight. After the coating solution was removed by

flicking the plate, various amounts of purified antagonist monoclonal antibodies in BLOTTO was added to each well and the plate was incubated at room temperature for one hour. Then the plate was washed with PBST, and 50  $\mu$ l of human ("h")IL-5R $\alpha$ /IgG4Fc chimeric protein at a  
365 final concentration of 0.5  $\mu$ g/ml was added to each well, continued at room temperature for one hour, and then washed with PBST. The plate was coated with HRP-conjugated goat anti-human IgG(Fc) for one hour and then peroxidase substrate solution was added to each well. The results for three different antibodies are shown in Fig. 1.

370 To determine the competition ability of the purified antagonist monoclonal antibodies obtained as above with human IL-5R $\alpha$ /IgG4Fc, an Immulon 2 plate was coated with 50  $\mu$ l/well (0.5  $\mu$ g/ml) of goat anti-mouse monoclonal antibody IgG(Fc) in PBS. Then the plate was washed with PBST and coated with 50  $\mu$ l/well (0.5  $\mu$ g/ml) of human IL-5R $\alpha$  antagonist  
375 monoclonal antibody 165-13 at room temperature for one hour. After washing with PBST, 100 $\mu$ l of BLOTTO containing the mixture of hIL-5R $\alpha$ /IgG4Fc (0.5  $\mu$ g/ml) and various amounts of antagonist antibodies obtained as above were added to each well, and incubated at room temperature for one hour. The plate was washed with PBST and HRP-  
380 conjugated goat anti-human IgG(Fc) was added. The results for three different antibodies are shown in Fig. 2.

monoclonal antibodies obtained in Example 8, a similar competitive ELISA as described above for screening antagonist antibodies was performed, except that after coating with human IL-5 at room temperature for one hour and washing with PBST, various amount of purified monoclonal antibodies with hIL-5R $\alpha$ /IgG4(Fc) at a final concentration of 0.5  $\mu$ g/ml was added to each well. After incubation at room temperature for one hour and washing with PBST, the same steps were conducted as described above for the competitive ELISA for screening the antagonist antibodies in hybridoma supernatants. The results for three different antibodies are shown in Fig. 3.

**Example 8. Purification of anti-human IL-5 receptor alpha chain antagonist monoclonal antibodies:**

The monoclonal antibodies generated from hybridomas described in Example 7 were purified by Prosep-A affinity chromatography, according to the manufacturer's instruction (Bioprocessing Inc., Princeton, NJ). The purity of these monoclonal antibodies was checked by SDS-PAGE and Western blot.

**Example 9. Proliferation inhibition assay of IL-5 dependent cells in the presence of hIL-5 by IL-5R antagonist monoclonal antibodies:**

TF-1 maintained in hIL-5 containing medium (RPMI-1640 + 10% FBS + 5 ng/ml hIL-5) was washed with hIL-5 free medium three time, and resuspended in a hIL-5 (Fig. 4(A)) or mouse ("m") IL-5 (Fig. 4(B)) containing medium (RPMI-1640 + 10% FBS + 0.6 ng/ml hIL-5 or mIL-5,

respectively) at a final cell density of  $2 \times 10^4/100 \mu\text{l}$ . Fifty microliters of TF-1 cells were added to each well of a 96-well plate. Fifty microliters of varying amounts of purified IL-5R $\alpha$  antagonist monoclonal antibodies obtained as above was added to each well. After three days of incubation, 10  $\mu\text{l}$  of MTT (2.5 mg/ml in PBS) was added to each well and incubated for 4 hours. One hundred  $\mu\text{l}$  of solubilization solution containing 10% SDS and 0.01 N HCl was added and the plate was incubated overnight. The proliferation of these IL-5 dependent TF-1 cells was monitored by reading at OD<sub>540-690</sub>.

**Example 10. Competitive inhibition assay of IL-5 dependent cells in the presence of hIL-5 by soluble human IL-5R $\alpha$  protein or antagonist monoclonal antibodies:**

TF-1 cells maintained in hIL-5 containing medium (RPMI-1640 + 10% FBS + 5 ng/ml hIL-5) were washed with IL-5-free medium three times and resuspended in hIL-5 containing medium (RPMI1640 + 10% FBS + 0.6 ng/ml hIL-5) at a final cell density of  $2 \times 10^4/100 \mu\text{l}$ . Fifty microliters of the cells was added to each well of a 96-well plate. Fifty microliter with varying amounts of purified hIL-5 alpha chain (R & D Biosystems) was added to each well. After three days of incubation, 10  $\mu\text{l}$  of MTT (2.5 mg/ml in PBS) was added to each well and incubation was continued for 4 hours. One hundred microliters of solubilization solution as described in Example 9 was added and the plate was incubated overnight. The proliferation of these IL-5 dependent TF-1 cells was monitored by reading at OD<sub>540-690</sub>.

at OD<sub>540-690</sub> The results for the antibody 165-13 against the hIL-5R $\alpha$  chain are shown in Fig. 5.

435 **Example 11. Adherence assay of IL-5 activated human eosinophils to a plastic culture plate immobilized with human IgG:**

Eosinophils were purified from a "buffy coat" collected from a healthy blood donor. The buffy coat was mixed with 3% Dextran T-500 (in 0.9% NaCl) at a 1:1 (v/v) ratio. The mixture was allowed to settle for 20  
440 minutes until a clearly defined interphase appeared. The upper layer was collected and centrifuged at 300 x g for 10 minutes at 4°C. The cell pellet was resuspended in phosphate-buffered saline (PBS) containing 1% bovine serum albumin. The cell suspension was layered on 10 ml of Ficoll-Paque in a 50-ml tissue culture tube. The tube was centrifuged at  
445 400xg for 40 minutes at 20°C. At the end of the centrifugation, the cell pellet which contains polymorphonuclear cells and red blood cells was collected. The red blood cells were then lysed using 0.83% ammonium chloride solution for 10 minutes at 4°C. The cell suspension was centrifuged and washed, and resuspended in 25 ml of 0.2% cold sodium  
450 chloride solution. 30 seconds later, 25 ml of 1.6% cold sodium chloride solution was added. The cell suspension was then centrifuged at 300 x g for 6 minutes at 4°C. The cell pellet was then resuspended in PBS and loaded on a Percoll gradients (density: 1.085, 1.090, 1.095 and 1.100 g/ml) in a tissue culture tube. The tube was centrifuged at 700 x g for 20  
455 minutes. At the end of the centrifugation, cells at the interphase of the

gradient 1.095/1.100 g/ml were collected. The cells contained mainly eosinophils.

For the adherence experiments, purified human IgG in PBS was added (1  $\mu$ g/well) to each well of 96-well tissue culture plates and  
460 incubated for 2 hours at 37°C. The plates were washed 3 times with PBS. The plates were then blocked with 50% (v/v) fetal bovine serum-PBS for 2 hours at 37°C. The plates were washed with adhesion medium (Hanks balanced salt solution with 0.9 mM  $\text{CaCl}_2$ , 0.5 mM  $\text{MgCl}_2$ , and 0.1% human serum albumin) to remove the blocking buffer. To each well, 50  $\mu$ l  
465 of either adhesion medium or recombinant IL-5 (100 pM) was added with 50  $\mu$ l of eosinophil suspension ( $10^5$  cells/ml in adhesion medium). One hundred microliters of anti-IL-5 monoclonal antibody 165-13 (produced, purified and screened as in the examples above) of different concentration were added in duplicate to the test wells. For negative control, an  
470 irrelevant isotype control monoclonal antibody was used. The plates were incubated for 30 minutes at 37°C, and then washed three times with the adhesion medium. The adherent eosinophils were lysed with 50  $\mu$ l of 0.3% (w/v) cetyl trimethylammonium bromide, followed by addition of 100  $\mu$ l of eosinophil peroxidase substrate (o-phenylenediamine). After 30  
475 minutes at room temperature, the color reaction was terminated by addition of 50  $\mu$ l of 2 M  $\text{H}_2\text{SO}_4$  and the  $\text{OD}_{490 \text{ nm}}$  read, after blanking on wells containing eosinophils.

direct measure of eosinophil peroxidase and was used as an indirect measure of the number of eosinophils adhered to each well and the binding ability of the antibody 165-13 to eosinophils. The results are shown in Fig. 6.

**Example 12: Epitope mapping of Anti-IL5 receptor antibodies**

**A. Constructing the human interleukin-5 receptor alpha chain epitope library.**

Seven micrograms of pcDNA3 plasmid containing the sequence coding for the human interleukin-5 receptor alpha chain (pcDNA3-IL-5R $\alpha$ ) was used to determine the conditions for DNase digestion which will yield 50-100 bp of DNA fragments. Aliquots of the plasmid were dissolved in DNase I buffer (50 mM Tris, pH7.6, 1 mM MnCl<sub>2</sub>, 0.1 mg/ml BSA) and placed in seven 1.5-ml eppendorf tubes. 3.5  $\mu$ l of seven different enzyme dilutions (0, 0.312, 0.625, 1.25, 2.5, 5, 10 units/ml) were added to the respective eppendorf tubes containing the plasmid, and all the tubes were incubated at 15°C for 10 minutes. The digestion was stopped by adding 2  $\mu$ l of 250 mM EDTA. The sample was loaded into each tube onto 2.5% agarose gel (SEAKEM LE agarose, FMC) for analysis. The enzyme dilution that gives the highest yield of 50-100 bp DNA fragments was selected. 20  $\mu$ g pcDNA3-IL-5R $\alpha$  was digested by using the selected enzyme digestion conditions. The DNA fragments were purified by phenol/chloroform extraction and ethanol precipitation, and redissolved in 100  $\mu$ l repair buffer (40 mM Tris-HCl, pH 8.0, 10 mM ammonium sulfate, 10 mM 2-



mercaptoethanol, 5 mM magnesium chloride, 0.5 mM EDTA, 100  $\mu$ M dNTP). The ends were repaired using 30 U of T4 DNA polymerase (NEB) at 15°C for one hour and 10 U of Klenow fragment (NEB) at 37°C for 30 minutes. The repaired DNA sample was loaded on a 2.5% low-melting agarose gel (SEAPLAQUE agarose, FMC) and 50-100 bp DNA fragments were isolated from the gel. The DNA was purified using gelase.

The concentration of the 50-100 bp DNA fragments was quantitated on 2.5% agarose gel. Using 10 U T4 ligase (BRL, 10U  $\mu$ l), the DNA fragments were ligated at 16°C overnight with a vector containing the blunt ends. The ligated DNA was purified through phenol/chloroform extraction and ethanol precipitation, and transformed into TG1 cells (*supE hsd $\Delta$ 5 thi  $\Delta$ (lac-proAB) F'[traD36 proAB<sup>+</sup> lac<sup>r</sup> lacZ $\Delta$ M15]*) by electroporation. About 2 million individual clones were obtained.

B. Screening for phage particles displaying the epitopes for antibodies.

The phage-display epitope library for IL-5R $\alpha$  was rescued from a 100-ml culture using the helper phage M13KO7. The resultant phage solution was concentrated using PEG precipitation (13% PEG8000, 0.15M NaCl). The concentrated phage library was panned against two anti-IL5R $\alpha$  murine antibodies, mAb165-4 (screened in as in Example 10) and mAb165-13, for three rounds (1st round, coat 5  $\mu$ g/ml mAb, wash 6 x PBST, 4 x PBS; 2nd round, coat 5  $\mu$ g/ml mAb, wash 10 x PBST, 3 x PBS;

characterization of individual phage clones using ELISA and DNA  
525 sequencing analysis.

C. Confirming the binding and analyzing the sequence of individual clones.

The individual clones were selected after three rounds of bio-panning and  
530 the phage particles derived from these individual clones were subjected to  
ELISA analysis. Four clones that bind to mAb 165-4 and five clones that  
bind to MAb 165-13 were sequenced and the sequencing results were  
aligned with the sequence of the human IL-5R $\alpha$  (SEQ ID NO: 1). The  
consensus sequence of all four mAb 165-4-binding clones was found to  
535 be as follows: Ser Ile Gln Trp Glu Lys Pro Val Ser Ala Phe Pro Ile His Cys  
Phe (SEQ ID NO.: 2, which is underlined in SEQ ID NO.: 1). No  
consensus sequence for MAb 165-13 was found, indicating that it binds to  
a conformational epitope. The specific methods of making certain murine  
antagonist antibodies of the invention are described below. As noted  
540 above, the same or similar methods can be used to generate other  
antibodies or antagonists of the invention.

It should be understood that the examples, terms and expressions  
used herein are exemplary only and not limiting, and that the invention is  
defined only in the claims which follow, and includes all equivalents of  
545 those claims.

## SEQUENCE LISTING

- (1) General Information:  
(i) Applicant: Yu, Liming; Sun, Bill; Sun, Cecily; Ni, Paul  
550 (ii) Title of Invention: IL-5R Antagonists for Treatment of Inflammation, Asthma and Other Allergic Diseases  
(iii) Number of Sequences: 4  
(iv) Correspondence Address:  
555 (A) Addressee: Tanox Biosystems, Inc.  
(B) Street: 10301 Stella Link Rd.  
(C) City: Houston  
(D) State: Texas  
(E) Country: USA  
560 (F) Zip: 77025  
(v) Computer Readable Form:  
(A) Medium Type: Diskette, 3.5 inch  
(B) Computer: Addonics C142 SVGA  
(C) Operating System: Microsoft Windows 95  
565 (D) Software: Word  
(vi) Current application data:  
(A) Application Number:  
(B) Filing Date:  
(C) Classification:  
570 (vii) Prior Application Data:  
(A) Application Number: 60/044,705  
(B) Filing Date: 18-04-1997  
(viii) Attorney/Agent Information:  
(A) Name: Mirabel, Eric P.  
575 (B) Registration Number: 31,211  
(C) Reference/Docket Number: 97-1-PCT  
(ix) Telecommunication Information:  
(A) Telephone: (713) 664-2288  
(B) Telefax: (713) 664-8914  
580 (2) Information for SEQ ID NO:1:  
(i) Sequence Characteristics:  
(A) Length: 419  
(B) Type: amino acid  
(C) Strandedness:  
585 (D) Topology: linear  
(ii) Molecule Type  
(A) Description: Sequence of the human IL-5 receptor protein  
(xi) Sequence Description: SEQ ID NO:1:  
590

Met Ile Ile Val Ala His Val Leu Leu Ile Leu Leu Gly

26

Ala Thr Glu Ile Leu Gln Ala Asp Leu Leu Pro Asp  
15 20 25  
595 Glu Lys Ile Ser Leu Leu Pro Pro Val Asn Phe Thr  
30 35  
Ile Lys Val Thr Gly Leu Ala Gln Val Leu Leu Gln  
40 45  
Trp Lys Pro Asn Pro Asp Gln Glu Gln Arg Asn Val  
600 50 55 60  
Asn Leu Glu Tyr Gln Val Lys Ile Asn Ala Pro Lys  
65 70  
Glu Asp Asp Tyr Glu Thr Arg Ile Thr Glu Ser Lys  
75 80 85  
605 Cys Val Thr Ile Leu His Lys Gly Phe Ser Ala Ser  
90 95  
Val Arg Thr Ile Leu Gln Asn Asp His Ser Leu Leu  
100 105  
Ala Ser Ser Trp Ala Ser Ala Glu Leu His Ala Pro  
610 110 115 120  
Pro Gly Ser Pro Gly Thr Ser Val Val Asn Leu Thr  
125 130  
Cys Thr Thr Asn Thr Thr Glu Asp Asn Tyr Ser Arg  
135 140 145  
615 Leu Arg Ser Tyr Gln Val Ser Leu His Cys Thr Trp  
150 155  
Leu Val Gly Thr Asp Ala Pro Glu Asp Thr Gln Tyr  
160 165  
Phe Leu Tyr Tyr Arg Tyr Gly Ser Trp Thr Glu Glu  
620 170 175 180  
Cys Gln Glu Tyr Ser Lys Asp Thr Leu Gly Arg Asn  
185 190

27

Ile Ala Cys Trp Phe Pro Arg Thr Phe Ile Leu Ser  
 195 200 205  
 625 Lys Gly Arg Asp Trp Leu Ala Val Leu Val Asn Gly  
 210 215  
 Ser Ser Lys His Ser Ala Ile Arg Pro Phe Asp Gln  
 220 225  
 Leu Phe Ala Leu His Ala Ile Asp Gln Ile Asn Pro  
 630 230 235 240  
 Pro Leu Asn Val Thr Ala Glu Ile Glu Gly Thr Arg  
 245 250  
 Leu Ser Ile Gln Trp Glu Lys Pro Val Ser Ala Phe  
 255 260  
 635 Pro Ile His Cys Phe Asp Tyr Glu Val Lys Ile His  
 265 270 275  
 Asn Thr Arg Asn Gly Tyr Leu Gln Ile Glu Lys Leu  
 280 285  
 Met Thr Asn Ala Phe Ile Ser Ile Ile Asp Asp Leu  
 640 290 295 300  
 Ser Lys Tyr Asp Val Gln Val Arg Ala Ala Val Ser  
 305 310  
 Ser Met Cys Arg Glu Ala Gly Leu Trp Ser Glu Trp  
 315 320  
 645 Ser Gln Pro Ile Tyr Val Gly Asn Asp Glu His Lys  
 325 330 335  
 Pro Leu Arg Glu Trp Phe Val Ile Val Ile Met Ala  
 340 345  
 Thr Ile Cys Phe Ile Leu Leu Ile Leu Ser Leu Ile  
 650 350 355 360  
 Cys Lys Ile Cys His Leu Thr Ile Leu Leu Ile

28

Pro Ile Pro Ala Pro Lys Ser Asn Ile Lys Asp Leu  
                   375                  380  
 655 Phe Val Thr Thr Asn Tyr Glu Lys Ala Gly Ser Ser  
                   385                  390                  395  
       Glu Thr Glu Ile Glu Val Ile Cys Tyr Ile Glu Lys Pro  
                   400                  405  
 660 Gly Val Glu Thr Leu Glu Asp Ser Val Phe  
                   410                  415

- (2) Information for SEQ ID NO:2:  
 (i) Sequence Characteristics:  
 665 (A) Length: 16 amino acids  
       (B) Type: amino acid  
       (C) Strandedness:  
       (D) Topology: linear  
       (ii) Molecule Type  
 670 (A) Description: Sequence of the portion of human IL-5  
       receptor protein bound by antibody 165-4  
       (xi) Sequence Description: SEQ ID NO:2:

675 Ser Ile Gln Trp Glu Lys Pro Val Ser Ala Phe Pro Ile His Cys Phe  
                   5                  10                  15

- (2) Information for SEQ ID NO:3:  
 (i) Sequence Characteristics:  
 680 (A) Length: 27  
       (B) Type: nucleotide  
       (C) Strandedness: single  
       (D) Topology: linear  
 685 (ii) Molecule Type  
       (A) Description: primer  
       (xi) Sequence Description: SEQ ID NO:3:

TAAAGCTTGA CAGGATATGA TCATCGT 27

- 690 (2) Information for SEQ ID NO:4:  
       (i) Sequence Characteristics:  
       (A) Length: 22  
       (B) Type: nucleotide  
       (C) Strandedness: single  
 695 (D) Topology: linear

- (ii) Molecule Type
- (A) Description: primer
- (xi) Sequence Description: SEQ ID NO:4:

700 TCGGATCCCA CATAAATAGG TT 22


WHAT IS CLAIMED IS:

1. Antagonist molecules which bind to the extracellular portion of the  $\alpha$  chain of the IL-5 receptor protein, and inhibit proliferation of eosinophils  
705 as measured in an *in vitro* assay to the same or a greater degree than do the antibodies designated 165-13 and 165-4.
2. Antagonist molecules which bind to the same epitopes as those bound by the antibodies designated 165-13 and 165-4.
3. Antagonist molecules which bind to a conformational epitope and inhibit  
710 proliferation of eosinophils as measured in an *in vitro* assay to the same or a greater degree than does the antibody designated 165-13.
4. The antagonist molecules of any of claims 1 to 3 which are monoclonal antibodies or homologues, analogues, or fragments thereof.
5. The antagonist molecules of claim 4 which are chimeric, humanized or  
715 human monoclonal antibodies.
6. The antagonist molecules of claim 4 which are  $V_H$ ,  $V_L$ ,  $F_v$ ,  $F_d$ ,  $Fab$  or  $(FAB')_2$  fragments of the murine, chimeric, humanized or human monoclonal antibodies.
7. Monoclonal antibodies having the same complementarity determining  
720 regions as the antibodies designated 165-13 or 165-4, or homologues, analogues or fragments thereof.
8. An antibody heavy chain having the same sequence as the antibodies




designated 165-13 or 165-4.

9. An antibody light chain having the same sequence as the antibodies  
725 designated 165-13 or 165-4.
10. An oligonucleotide encoding the antibody light or heavy chain of the  
antibody of claim 7.
11. An oligonucleotide encoding the sequence of the heavy or light chains  
of claims 9 or 10, respectively.
- 730 12. A host cell transfected with the oligonucleotide of claim 10.
13. A host cell transfected with the oligonucleotide of claim 11.
14. A process of making an antagonist to human IL-5 receptor, comprising:  
(a) isolating molecules which bind to the human IL-5 receptor alpha  
chain;  
735 (b) isolating the molecules from step (a) which compete with IL-5 for  
binding to the receptor protein.
15. The process of claim 14, further comprising the step of isolating the  
molecules which inhibit eosinophil proliferation *in vivo*.




SUBSTITUTE SHEET (RULE 26)

Figure 2



SUBSTITUTE SHEET (RULE 26)

Figure 3



SUBSTITUTE SHEET (RULE 26)

Figure 4 (A)




Figure 4 (B)




Figure 5





Figure 6



SUBSTITUTE SHEET (RULE 26)



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/07810

## A CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 16/28; C07H 21/04; C12N 5/10; C12P 21/08; A61K 39/395

US CL : 530/388.22; 536/23.53; 435/325, 334, 70.1; 424/144.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/388.22; 536/23.53; 435/325, 334, 70.1; 424/144.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG biotech cluster

terms: interleukin 5, receptor, alpha, antibody, eosinophil?

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,455,337 A (DEVOS et al) 03 October 1995, especially examples 1 and 3.	1-8, 10-15



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	
*O* document referring to an oral disclosure, use, exhibition or other means	

Date of the actual completion of the international search

03 JUNE 1998

Date of mailing of the international search report

17 JUL 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT

Authorized officer

Facsimile No. (703) 305 3230

Telephone No. (703) 308 0196

Form PCT/ISA/210 (second sheet) July 1992

